Amgen and AstraZeneca to Axe Jobs
Biotech giant Amgen (Thousand Oaks, CA, www.amgen.com) will shrink its workforce by 12–14 %, or approximately 2,200–2,600 employees, as part of its strategy to save more than $1 billion next year.
Biotech giant Amgen (Thousand Oaks, CA, www.amgen.com) will shrink its workforce by 12–14 %, or approximately 2,200–2,600 employees, as part of its strategy to save more than $1 billion next year. AstraZeneca (London, UK, www.astrazeneca.com) also plans to cut 7,600 jobs worldwide by 2010, more than double the amount announced earlier this year.
The job cuts at Amgen follow a series of recent clinical and regulatory setbacks, particularly involving Aranesp, its top-selling anemia drug. The company plans to complete its restructuring by 2008 and the changes will yield pre-tax savings of $1.0–$1.3 billion in 2008. The company also plans to close certain production operations and reduce the size of other units to become more efficient.
The AstraZeneca news comes after the company announced that second-quarter earnings fell to $1.43 billion, down from $1.6 billion a year ago, following its $15.6 billion acquisition of Maryland-based biotech MedIummune in April. Earlier this year, the company had announced it would cut 3,000 jobs by 2010 to compensate for anticipated losses from generic competition. The company aims to save more than $900 million annually by 2010 through restructuring.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
